Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 6/20 | 0.53 |
| ▸ | RARB | P10826 | 6/20 | 0.53 |
| ▸ | RARG | P13631 | 6/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | RARA | P10276 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 8/20 | 0.51 |
| ▸ | RXRB | P28702 | 8/20 | 0.51 |
| ▸ | RXRG | P48443 | 8/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | BLVRB | P30043 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934121 | 0.91 | RARB (0.58) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3936415 | 0.89 | MEN1 (0.54) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3934819 | 0.89 | RARB (0.54) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3933071 | 0.83 | RARB (0.58) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3931644 | 0.82 | RARB (0.56) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3931570 | 0.81 | RARB (0.56) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL6335053 | 0.81 | RARB (0.58) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL3936079 | 0.81 | LMNA (0.56) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL8675649 | 0.80 | RXRA (0.62) | CYP26A1RARBRARGCYP3A4RARA | |
| SCHEMBL6342047 | 0.80 | RXRA (0.57) | CYP26A1RARBRARGCYP3A4RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430023-B1 | SUBSTITUIED UREA RETINOID AGONISTS II | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6838472-B2 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1430023-A1 | SUBSTITUIED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-20030125383-A1 | Substituted urea retinoid agonists | ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) LLC | 2003-07-03 | — | — | US | disclosed |
| WO-2003024920-A1 | SUBSTITUTED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125383-A1 | Substituted urea retinoid agonists | RXRA, RXRG, RARG | CYP26A1 801/4885RARB 6/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.